Exploiting EP2 receptor biology to target seizure-related neuroinflammation selectively

利用 EP2 受体生物学选择性地靶向癫痫相关的神经炎症

基本信息

  • 批准号:
    10171930
  • 负责人:
  • 金额:
    $ 52.02万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-06-01 至 2025-02-28
  • 项目状态:
    未结题

项目摘要

Project Summary Accumulating evidence in humans and in animal models indicates that inflammation of the brain that develops after status epilepticus (SE) may play a determinant role in long-term detrimental consequences, independent of an infection or auto-immune cause. The pathophysiological interactions among the various inflammatory molecules, and the sequence of events leading to their induction, have not yet been dissected. Previous work pointed to a role for cyclooxygenase-2 (COX-2) pathways in SE-induced inflammation, and showed that the EP2 receptor mediates much of the COX-2 effect. Our recent work suggests that PGE2 released from neurons after SE activates EP2 receptors on nearby neurons and myeloid cells, and that EP2 activation on neurons and myeloid cells might cause opposing effects. We hypothesize that EP2 activation on neurons after SE is neuroprotective, whereas EP2 activation on microglia or invading monocytes results in cytokine synthesis and subsequent development of epilepsy. Here we use a novel HaloTag technology to target neurons and myeloid cells separately with EP2 antagonists and agonists to test this hypothesis. Our specific aims are: 1. To test the hypothesis that pharmacologic block of EP2 receptors on neurons and myeloid cells has opposing effects after SE. 2. To test the hypothesis that blocking EP2 receptors on myeloid cells interferes with the process of epileptogenesis. 3. To test the hypothesis that EP2-mediated neuroprotection involves neuronal EP2 receptors, utilizes a cAMP rather than β-arrestin pathway, and requires CX3CL1 (fractalkine). To address these aims we employ in vitro culture models and in vivo SE models with novel EP2 antagonists and agonists targeted by HaloTag to neurons or microglia. Immunohistochemical, western blot, qRT-PCR, cell viability, EEG and behavioral assays are performed.
项目摘要 在人类和动物模型中积累的证据表明,大脑的炎症 癫痫持续状态(SE)可能在长期有害后果中起决定性作用, 不受感染或自身免疫因素影响的。不同组织之间的病理生理相互作用 炎症分子以及导致其诱发的一系列事件尚未被剖析。 以前的工作指出了环氧合酶-2(COX-2)通路在SE诱导的炎症中的作用,以及 研究表明,EP2受体在很大程度上介导了COX-2效应。我们最近的研究表明,PGE2 在SE激活附近神经元和髓细胞上的EP2受体后,神经元释放的EP2,而EP2 对神经元和髓系细胞的激活可能会导致相反的效果。我们假设EP2的激活 SE后对神经元的影响是神经保护的,而EP2对小胶质细胞或侵袭性单核细胞的激活会导致 参与细胞因子的合成和癫痫的后续发展。在这里,我们使用一种新的HaloTag技术来 用EP2拮抗剂和激动剂分别靶向神经元和髓系细胞来验证这一假说。我们的 具体目的是:1.检验EP2受体的药物阻断对神经元和 髓系细胞在SE后具有相反的作用。2.验证阻断髓系EP2受体的假说 细胞干扰癫痫的发生过程。3.检验EP2介导的假说 神经保护涉及神经元EP2受体,利用cAMP而不是β-arrestin途径,以及 需要CX3CL1(Fractalkine)。为了达到这些目的,我们采用了体外培养模型和活体SE HaloTag靶向神经元或小胶质细胞的新型EP2拮抗剂和激动剂的模型。 免疫组织化学、Western印迹、qRT-PCR、细胞活力、脑电和行为学检测。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAYMOND J DINGLEDINE其他文献

RAYMOND J DINGLEDINE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAYMOND J DINGLEDINE', 18)}}的其他基金

Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits
针对癫痫发作后认知缺陷的 EP2 拮抗剂的优化
  • 批准号:
    10467539
  • 财政年份:
    2022
  • 资助金额:
    $ 52.02万
  • 项目类别:
Optimization of EP2 Antagonists for Post-Seizure Cognitive Deficits
针对癫痫发作后认知缺陷的 EP2 拮抗剂的优化
  • 批准号:
    10732636
  • 财政年份:
    2022
  • 资助金额:
    $ 52.02万
  • 项目类别:
Exploiting EP2 receptor biology to target seizure-related neuroinflammation selectively
利用 EP2 受体生物学选择性地靶向癫痫相关的神经炎症
  • 批准号:
    10356163
  • 财政年份:
    2020
  • 资助金额:
    $ 52.02万
  • 项目类别:
Exploiting EP2 receptor biology to target seizure-related neuroinflammation selectively
利用 EP2 受体生物学选择性地靶向癫痫相关的神经炎症
  • 批准号:
    10570244
  • 财政年份:
    2020
  • 资助金额:
    $ 52.02万
  • 项目类别:
Probing the Protective Role of EZH2 in Epilepsy
探讨 EZH2 在癫痫中的保护作用
  • 批准号:
    10617699
  • 财政年份:
    2019
  • 资助金额:
    $ 52.02万
  • 项目类别:
Probing the Protective Role of EZH2 in Epilepsy
探讨 EZH2 在癫痫中的保护作用
  • 批准号:
    10398140
  • 财政年份:
    2019
  • 资助金额:
    $ 52.02万
  • 项目类别:
Inflammatory control of blood-brain barrier integrity and epileptogenesis after seizures
癫痫发作后血脑屏障完整性和癫痫发生的炎症控制
  • 批准号:
    9272954
  • 财政年份:
    2016
  • 资助金额:
    $ 52.02万
  • 项目类别:
Inflammatory control of blood-brain barrier integrity and epileptogenesis after seizures
癫痫发作后血脑屏障完整性和癫痫发生的炎症控制
  • 批准号:
    9914359
  • 财政年份:
    2016
  • 资助金额:
    $ 52.02万
  • 项目类别:
Inflammatory control of blood-brain barrier integrity and epileptogenesis after seizures
癫痫发作后血脑屏障完整性和癫痫发生的炎症控制
  • 批准号:
    9159612
  • 财政年份:
    2016
  • 资助金额:
    $ 52.02万
  • 项目类别:
Regulation of epileptogenesis by the transcriptional repressor, REST
转录抑制因子 REST 对癫痫发生的调节
  • 批准号:
    8325008
  • 财政年份:
    2011
  • 资助金额:
    $ 52.02万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 52.02万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了